Next Article in Journal
Comparative Pulmonary Toxicity of Two Ceria Nanoparticles with the Same Primary Size
Next Article in Special Issue
ADMA/SDMA in Elderly Subjects with Asymptomatic Carotid Atherosclerosis: Values and Site-Specific Association
Previous Article in Journal
PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy
Previous Article in Special Issue
Effect of Lowering Asymmetric Dimethylarginine (ADMA) on Vascular Pathology in Atherosclerotic ApoE-Deficient Mice with Reduced Renal Mass
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 15
Issue 4
10.3390/ijms15046062
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD)

by
Jeremy A. Scott
1,
MyLinh Duongh
2,
Aaron W. Young
3,
Padmaja Subbarao
4,
Gail M. Gauvreau
2 and
Hartmut Grasemann
4,*
1
Department of Health Sciences, Lakehead University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada
2
Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada
3
Department of Physiology and Biophysics, Boston University School of Medicine, 72 East Concord St., Boston, MA 02118, USA
4
Program in Physiology and Experimental Medicine, SickKids Research Institute, and Division of Respiratory Medicine, Department of Pediatrics, Hospital for Sick Children, 555 University Avenue University of Toronto, Toronto, ON M5G 1X8, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(4), 6062-6071; https://doi.org/10.3390/ijms15046062
Submission received: 30 December 2013 / Revised: 7 March 2014 / Accepted: 31 March 2014 / Published: 10 April 2014
(This article belongs to the Special Issue ADMA and Nitrergic System)
Browse Figures
Versions Notes

Abstract

:
l-Arginine metabolism including the nitric oxide (NO) synthase and arginase pathways is important in the maintenance of airways function. We have previously reported that accumulation of asymmetric dimethylarginine (ADMA) in airways, resulting in changes in l-arginine metabolism, contributes to airways obstruction in asthma and cystic fibrosis. Herein, we assessed l-arginine metabolism in airways of patients with chronic obstructive pulmonary disease (COPD). Lung function testing, measurement of fractional exhaled NO (FeNO) and sputum NO metabolites, as well as quantification of l-arginine metabolites (l-arginine, l-ornithine, l-citrulline, ADMA and symmetric dimethylarginine) using liquid chromatography-mass spectrometry (LC-MS) were performed. Concentrations of l-ornithine, the product of arginase activity, correlated directly with l-arginine and ADMA sputum concentrations. FeNO correlated directly with pre- and post-bronchodilator forced expiratory volume in one second (FEV1). Sputum arginase activity correlated inversely with total NO metabolite (NOx) and nitrite concentrations in sputum, and with pre- and post-bronchodilator FEV1. These findings suggest that ADMA in COPD airways results in a functionally relevant shift of l-arginine breakdown by the NO synthases towards the arginase pathway, which contributes to airway obstruction in these patients.

1. Introduction

l-Arginine metabolism plays an important role in the maintenance of airways tone and function by production of nitric oxide (NO) and l-citrulline, via the NO synthase (NOS) pathway, as well as l-ornithine and the polyamines, via arginase and ornithine decarboxylase, respectively (Figure 1) [1,2]. Dysregulation of the competing enzymes has been shown to contribute to airway obstruction in asthma and in patients with cystic fibrosis [3–5]. Sputum arginase activity is increased in both diseases [2,6–9] and leads to decreased availability of l-arginine substrate for NOS, and subsequently to relative airway NO deficiency. NO is necessary for airway smooth muscle relaxation, and NO deficiency results in airways hyperreactivity [1,2,10,11]. Of the three NOS isozymes, the neuronal and endothelial isoforms are constitutively expressed in airways and contribute to the maintenance of airways smooth muscle tone [12]. The third isoform, the inducible NOS (NOS2) is upregulated in airways inflammation (i.e., airway epithelial cells isolated from patients with asthma [1,13,14]. Thus, the balance between the NOS isozymes and arginases contributes to the tight regulation of airways tone in health and disease.
Recent evidence suggests that arginase controls NOS activity in airways not only through limitation of l-arginine bioavailability, but also by producing l-ornithine, the precursor of polyamine biosynthesis [15,16]. The polyamine spermine, which acts as an inhibitor of NOS, is increased in asthma and CF airways [15,16]. We recently demonstrated in the mouse that nebulization of spermine into the airways led to airways hyperreponsiveness to methacholine, which was mediated via a decrease in airway NO [16]. The shift of l-arginine metabolism toward the arginase pathway has been suggested to contribute to remodeling of asthma airways, due to the production of polyamines [12,16] and of proline, which is a precursor of the deposition of collagen [1,14,17].
NOS activity can also be reduced by the accumulation of endogenous inhibitors such as ADMA, a product of protein degradation that has only recently been recognized as being associated with lung disease [3–5,18,19]. ADMA has long been found to be associated with renal failure [20,21] and cardiovascular disease [22,23]. However, we recently reported increased levels of ADMA in asthma and cystic fibrosis airways [3–5], which likely contributes to NO imbalance and respiratory dysfunction.
Chronic obstructive pulmonary disease (COPD) is clinically characterized by persistent productive cough, mucous plugging, airway obstruction, and progressive airflow limitation on pulmonary function testing [24]. While there has been some evidence for increased arginase expression in airways of smokers with asthma [25] and COPD [26] and altered inducible NO synthase expression in COPD [26], a clear picture of the l-arginine metabolism in the COPD airways remains to be elucidated. Further studies have shown increased arginase expression and/or activity in serum [27], erythrocytes and platelets [28], and bronchoalveolar lavage samples [29] from COPD patients, which have been supported by findings in mouse [29] and guinea pig [30] COPD models. Thus, we quantified the l-arginine metabolites l-arginine, l-ornithine and l-citrulline, as well as surrogate markers of NO synthase activity (FeNO and NOx) and dysfunction (the endogenous competitive NOS inhibitor ADMA) in sputum samples obtained from patients with COPD and examined their relationship(s) with the outcomes of lung function testing.

2. Results and Discussion

2.1. Patient Demographics and Lung Function

Lung function testing of COPD patients revealed severe airflow limitation; with a mean pre-bronchodilator FEV1 of 1.2 ± 0.1 L (39.6% ± 4.0% predicted) and a significant bronchodilator response (BDR) after inhaled salbutamol of 25.6% ± 4.4% (post-bronchodilator FEV1 of 1.5 ± 0.2 L; 49.4% ± 4.8% predicted); thus, severe COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] Classification 3) [24]. Patient demographics are presented in Table 1.

2.2. Sputum l-Arginine Metabolites and Indices of Arginase and NO Synthase Activity

Sputum concentrations of l-arginine metabolites (i.e., l-arginine, l-citrulline, l-ornithine, ADMA and SDMA) are shown in Figure 2, and sputum NO metabolites (NOx, nitrite levels) and in vitro arginase activity in Table 2. While the l-arginine metabolites were measureable in all COPD samples, the measured concentrations appeared to be lower than in previous studies of CF and asthma sputum samples, but higher than in healthy controls [3,4,31]. While this observation could at least in part be explained by differences in sputum processing, it was interesting to us that the l-arginine/ADMA ratio, an index of NOS impairment, was similar between CF, asthma and COPD sputum samples [6]. Sub-group analyses including smoking state (current/ex-smokers) and inhaled glucocorticosteroid use did not reveal differences, possibly due to the small sample sizes.

2.3. Correlations between Sputum Measures of l-Arginine Metabolites and Arginase Activity

To determine the relationship of the different sputum l-arginine metabolites, we calculated Spearman’s correlation values for each of the parameters. Interestingly, among these measures, l-ornithine correlated directly with l-arginine and ADMA levels in sputum, but not with in vitro arginase activity (Figure 3). As l-arginine is the precursor of l-ornithine production along the arginase metabolic pathway, this correlation may be expected. However, the direct and significant correlation between sputum l-ornithine and ADMA levels, which would appear to be due to two independent pathways (i.e., arginase activity and protein turnover, respectively) suggests that higher concentrations of the endogenous NOS inhibitor ADMA result in increased availability of l-arginine for the arginase pathway and subsequently leads to the increased formation of l-ornithine. Such a shift in the NO synthase/arginase balance had previously been suggested to contribute to airways hyperresponsiveness in asthma [2,7], and there has also been evidence from studies in human bronchi that arginase was responsible for exacerbating respiratory sensitivity to spasmogens in COPD patients [26]. There was no correlation of ADMA with FeNO or sputum NOx concentrations. ADMA did however correlate with l-citrulline concentrations in sputum (Spearman r = 0.8651; p = 0.0023), which may be explained by the fact that l-citrulline is not only a product of NOS activity but also of ADMA degradation by DDAH [32]. Arginase activity in COPD sputum was 5-fold higher compared to previously reported activities in healthy controls [6]. The observation that sputum arginase activity also did not exhibit significant correlations with ADMA may be explained by the experimental conditions of the in vitro assay, which was performed using excess substrate concentrations, and may therefore not be reflective of arginase activity in vivo.

2.4. Correlations between Sputum l-Arginine Metabolites, Expired NO, Arginase Activity and Lung Function

Based upon our hypothesis that increased ADMA results in reduced NO synthesis, and the fact that NO deficiency has been associated with airflow limitation and airway responsiveness in other respiratory diseases [1,2,10,33,34], it is interesting that the fraction of expired NO (FeNO) in the COPD patients correlated significantly and positively with both pre- and post-bronchodilator FEV1 (Figure 4), but not with the bronchodilator induced changes in FEV1. All FeNO results were within published normal ranges [35] suggesting that measurements of FeNO may not be helpful to detect abnormalities in the NO metabolism in these patients.
Further examination of the relationship between arginase activities and levels of NO metabolites (i.e., NOx, and nitrite) in sputum supported an association between increased arginase activity and impaired production of airway NO. This was further strengthened by the observation that arginase activity correlated significantly and inversely with both pre and post-bronchodilator FEV1%predicted (Figure 5).

3. Experimental Section

Ten patients with physician-diagnosed COPD [24] were recruited for two independent visits in stable clinical condition. The fraction of exhaled NO (FeNO) [36,37] as well as pulmonary function testing before and after the administration of 400 mcg of salbutamol via metered dose inhaler [38] were measured according to published guidelines of the European Respiratory Society and American Thoracic Society on the first of the two visits, respectively. Sputum specimens were obtained on both visits, mixed with lysis buffer (0.1% Triton X-100 plus added protease inhibitors), homogenized, aliquoted and stored at −80 °C prior to further processing. Sputum specimens were analyzed for l-arginine, l-ornithine and l-citrulline, the endogenous NOS inhibitor ADMA, as well as SDMA using liquid chromatography-tandem mass spectrometry (LC-MS/MS), as previously described [3,4]. Briefly, samples were butylated after deproteinization, separated by high-performance liquid chromatography, and then subjected to mass spectrometry. Concentrations were determined by comparison with standard curves prepared and processed in a similar manner as the sputum samples. Sputum nitrite, NOx, and in vitro arginase activities were measured using spectrophotometric approaches, as described previously [16].
After testing for normality of the distribution of the data, we determined that non-parametric statistical analyses were appropriate. Spearman’s correlations were determined between measures using GraphPad Prism (Version 6.0d, GraphPad Software Inc., LaJolla, CA, USA).

4. Conclusions

This is the first assessment of the complex l-arginine metabolism in airways of patients with COPD. Our preliminary analysis demonstrates the presence of the competitive NOS inhibitor ADMA in COPD sputum. The significant correlations between ADMA and l-ornithine, the product of arginase activity, and of arginase activity and NOx, suggests that accumulation of ADMA in the airways of COPD patients results in a shunt of l-arginine away from NO synthases towards the arginase pathway. The correlation of both arginase activity and FeNO with pre- and post-bronchodilator FEV1, further suggests that the observed alterations in the l-arginine metabolism have significant functional consequences for these patients. Increased arginase activity may also contribute to the chronically progressing structural alterations (remodeling) of the COPD airways. It is important to note though, that the alterations in the l-arginine metabolism were not reflected in abnormal FeNO. Further studies are needed to help understand whether sputum analyses could be helpful to assess the effects of therapeutic interventions on the l-arginine metabolism in COPD.

Acknowledgments

Mass spectrometry analyses were performed at the Analytical Facility for Bioactive Molecules (AFBM) of the Centre for the Study of Complex Childhood Diseases (CSCCD), the Hospital for Sick Children, Toronto, Ontario. The CSCCD was supported by the Canadian Foundation for Innovation (CFI).
We would also like to thank Jalil Nasiri for technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.
  • Author ContributionsJAS: Analysis and interpretation of data, drafting and revision of the manuscript; MLD: Patient recruitment, acquisition and analysis of data, and revising of the manuscript; AWY: Patient recruitment, acquisition and analysis of data, and revision of the manuscript; PS: Drafting and revision of the manuscript; GMG: Study design, patient recruitment, acquisition and analysis of data, drafting and revision of the manuscript; HG: Study design, analysis and interpretation of data, drafting and revision of the manuscript.

References

  1. North, M.L.; Scott, J.A. l-Arginine metabolism in the lung: Reciprocal regulation of the NOS and arginase pathways. Open Nitric Oxide J 2011, 3 Suppl 1-M7, 48–54. [Google Scholar]
  2. Maarsingh, H.; Pera, T.; Meurs, H. Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch. Pharmacol 2008, 378, 171–184. [Google Scholar]
  3. Grasemann, H.; Al-Saleh, S.; Scott, J.A.; Shehnaz, D.; Mehl, A.; Amin, R.; Rafii, M.; Pencharz, P.; Belik, J.; Ratjen, F. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med 2011, 183, 1363–1368. [Google Scholar]
  4. Scott, J.A.; North, M.L.; Rafii, M.; Huang, H.; Pencharz, P.; Subbarao, P.; Belik, J.; Grasemann, H. Asymmetric dimethylarginine is increased in asthma. Am. J. Respir. Crit. Care Med 2011, 184, 779–785. [Google Scholar]
  5. Scott, J.A.; Grasemann, H. Asymmetric dimethylarginine: A disease marker for asthma? Chest 2013, 144, 367–368. [Google Scholar]
  6. Grasemann, H.; Schwiertz, R.; Matthiesen, S.; Racke, K.; Ratjen, F. Increased arginase activity in cystic fibrosis airways. Am. J. Respir. Crit. Care Med 2005, 172, 1523–1528. [Google Scholar]
  7. North, M.L.; Khanna, N.; Marsden, P.A.; Grasemann, H.; Scott, J.A. Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. Am. J. Physiol. Lung Cell. Mol. Physiol 2009, 296, L911–L920. [Google Scholar]
  8. Zimmermann, N.; King, N.E.; Laporte, J.; Yang, M.; Mishra, A.; Pope, S.M.; Muntel, E.E.; Witte, D.P.; Pegg, A.A.; Foster, P.S.; et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Investig 2003, 111, 1863–1874. [Google Scholar]
  9. Zimmermann, N.; Rothenberg, M.E. The arginine-arginase balance in asthma and lung inflammation. Eur. J. Pharmacol 2006, 533, 253–262. [Google Scholar]
  10. Gaston, B.; Drazen, J.M.; Loscalzo, J.; Stamler, J.S. The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med 1994, 149, 538–551. [Google Scholar]
  11. Morris, C.R. Arginine and asthma. Nestle Nutr. Inst. Workshop Ser 2013, 77, 1–15. [Google Scholar]
  12. Meurs, H.; McKay, S.; Maarsingh, H.; Hamer, M.A.; Macic, L.; Molendijk, N.; Zaagsma, J. Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br. J. Pharmacol 2002, 136, 391–398. [Google Scholar]
  13. Meurs, H.; Maarsingh, H.; Zaagsma, J. Arginase and asthma: Novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol. Sci 2003, 24, 450–455. [Google Scholar]
  14. North, M.L.; Meurs, H.; Zaagsma, J.; Scott, J.A.; Maarsingh, H. Arginase in asthma—Recent developments in animal and human studies. Open Nitric Oxide J 2010, 2, 20–36. [Google Scholar]
  15. Grasemann, H.; Shehnaz, D.; Enomoto, M.; Leadley, M.; Belik, J.; Ratjen, F. l-ornithine derived polyamines in cystic fibrosis airways. PLoS One 2012, 7, e46618. [Google Scholar]
  16. North, M.L.; Grasemann, H.; Khanna, N.; Inman, M.D.; Gauvreau, G.M.; Scott, J.A. Increased ornithine-derived polyamines cause airway hyperresponsiveness in a mouse model of asthma. Am. J. Respir. Cell. Mol. Biol 2013, 48, 694–702. [Google Scholar]
  17. Tanaka, H.; Masuda, T.; Tokuoka, S.; Komai, M.; Nagao, K.; Takahashi, Y.; Nagai, H. The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. Inflamm. Res 2001, 50, 616–624. [Google Scholar]
  18. Holguin, F.; Comhair, S.A.; Hazen, S.L.; Powers, R.W.; Khatri, S.S.; Bleecker, E.R.; Busse, W.W.; Calhoun, W.J.; Castro, M.; Fitzpatrick, A.M.; et al. An association between l-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am. J. Respir. Crit. Care Med 2013, 187, 153–159. [Google Scholar]
  19. Lara, A.; Khatri, S.B.; Wang, Z.; Comhair, S.A.; Xu, W.; Dweik, R.A.; Bodine, M.; Levison, B.S.; Hammel, J.; Bleecker, E.; et al. Alterations of the arginine metabolome in asthma. Am. J. Respir. Crit. Care Med 2008, 178, 673–681. [Google Scholar]
  20. Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339, 572–575. [Google Scholar]
  21. Schwedhelm, E.; Boger, R.H. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat. Rev. Nephrol 2011, 7, 275–285. [Google Scholar]
  22. Kurz, K.; Teerlink, T.; Sarcletti, M.; Weiss, G.; Zangerle, R.; Fuchs, D. Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol. Res 2009, 60, 508–514. [Google Scholar]
  23. Boger, R.H.; Maas, R.; Schulze, F.; Schwedhelm, E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality—An update on patient populations with a wide range of cardiovascular risk. Pharmacol. Res 2009, 60, 481–487. [Google Scholar]
  24. Vestbo, J.; Hurd, S.S.; Agusti, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M.; et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med 2013, 187, 347–365. [Google Scholar]
  25. Bergeron, C.; Boulet, L.P.; Page, N.; Laviolette, M.; Zimmermann, N.; Rothenberg, M.E.; Hamid, Q. Influence of cigarette smoke on the arginine pathway in asthmatic airways: Increased expression of arginase I. J. Allergy Clin. Immunol 2007, 119, 391–397. [Google Scholar]
  26. Tadie, J.M.; Henno, P.; Leroy, I.; Danel, C.; Naline, E.; Faisy, C.; Riquet, M.; Levy, M.; Israel-Biet, D.; Delclaux, C. Role of nitric oxide synthase/arginase balance in bronchial reactivity in patients with chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol 2008, 294, L489–L497. [Google Scholar]
  27. Scrimini, S.; Pons, J.; Agusti, A.; Soriano, J.B.; Cosio, B.G.; Torrecilla, J.A.; Nunez, B.; Cordova, R.; Iglesias, A.; Jahn, A.; et al. Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. Respir Med 2013, 107, 1895–1903. [Google Scholar]
  28. Guzman-Grenfell, A.; Nieto-Velazquez, N.; Torres-Ramos, Y.; Montoya-Estrada, A.; Ramirez-Venegas, A.; Ochoa-Cautino, L.; Flores-Trujillo, F.; Hicks, J.J. Increased platelet and erythrocyte arginase activity in chronic obstructive pulmonary disease associated with tobacco or wood smoke exposure. J. Investig. Med 2011, 59, 587–592. [Google Scholar]
  29. Hodge, S.; Matthews, G.; Mukaro, V.; Ahern, J.; Shivam, A.; Hodge, G.; Holmes, M.; Jersmann, H.; Reynolds, P.N. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am. J. Respir. Cell. Mol. Biol 2011, 44, 673–681. [Google Scholar]
  30. Pera, T.; Zuidhof, A.B.; Smit, M.; Menzen, M.H.; Klein, T.; Flik, G.; Zaagsma, J.; Meurs, H.; Maarsingh, H. Arginase inhibition prevents inflammation and remodeling in a guinea pig model of COPD. J. Pharmacol. Exp. Ther 2014. [Google Scholar] [CrossRef]
  31. Grasemann, H.; Tullis, E.; Ratjen, F. A randomized controlled trial of inhaled l-arginine in patients with cystic fibrosis. J. Cyst. Fibros 2013, 12, 468–474. [Google Scholar]
  32. Zakrzewicz, D.; Eickelberg, O. From arginine methylation to ADMA: A novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm. Med 2009. [Google Scholar] [CrossRef]
  33. Gaston, B. The biochemistry of asthma. Biochim. Biophys. Acta 2011, 1810, 1017–1024. [Google Scholar]
  34. Maarsingh, H.; Zaagsma, J.; Meurs, H. Arginine homeostasis in allergic asthma. Eur. J. Pharmacol 2008, 585, 375–384. [Google Scholar]
  35. See, K.C.; Christiani, D.C. Normal values and thresholds for the clinical interpretation of exhaled nitric oxide levels in the US general population: Results from the National Health and Nutrition Examination Survey 2007–2010. Chest 2013, 143, 107–116. [Google Scholar]
  36. Dweik, R.A.; Boggs, P.B.; Erzurum, S.C.; Irvin, C.G.; Leigh, M.W.; Lundberg, J.O.; Olin, A.C.; Plummer, A.L.; Taylor, D.R. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med 2011, 184, 602–615. [Google Scholar]
  37. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med 2005, 171, 912–930.
  38. Brusasco, V.; Crapo, R.; Viegi, G. Coming together: The ATS/ERS consensus on clinical pulmonary function testing. Eur. Respir. J 2005, 26, 1–2. [Google Scholar]
Ijms 15 06062f1 1024
Figure 1. Schema of l-arginine metabolism via the NO synthase (NOS) and arginase pathways to nitric oxide (NO) and l-citrulline, and urea and l-ornithine, respectively. l-Ornithine is metabolized by ornithine decarboxylase (ODC) to polyamines, which can block NOS activity, or by ornithine aminotransferase (OAT), which provides proline, a precursor of collagen biosynthesis. l-Arginine is also incorporated into proteins, where it can be mono- or di-methylated by protein arginine methyltransferases (PRMT), allowing the liberation of monomethyl arginine (MMA) and asymmetric dimethylarginine (ADMA) during proteolysis, which act as endogenous inhibitors of NOS, as well as symmetric dimethylarginine (SDMA), which competes with l-arginine for uptake by the cationic amino acid transporter-2 [1].
Figure 1. Schema of l-arginine metabolism via the NO synthase (NOS) and arginase pathways to nitric oxide (NO) and l-citrulline, and urea and l-ornithine, respectively. l-Ornithine is metabolized by ornithine decarboxylase (ODC) to polyamines, which can block NOS activity, or by ornithine aminotransferase (OAT), which provides proline, a precursor of collagen biosynthesis. l-Arginine is also incorporated into proteins, where it can be mono- or di-methylated by protein arginine methyltransferases (PRMT), allowing the liberation of monomethyl arginine (MMA) and asymmetric dimethylarginine (ADMA) during proteolysis, which act as endogenous inhibitors of NOS, as well as symmetric dimethylarginine (SDMA), which competes with l-arginine for uptake by the cationic amino acid transporter-2 [1].
Ijms 15 06062f1
Ijms 15 06062f2 1024
Figure 2. Sputum l-arginine metabolite (l-arginine, l-citrulline, l-ornithine) (A); and ADMA and SDMA (B), concentrations in COPD patients. Data are expressed as the mean ± SEM.
Figure 2. Sputum l-arginine metabolite (l-arginine, l-citrulline, l-ornithine) (A); and ADMA and SDMA (B), concentrations in COPD patients. Data are expressed as the mean ± SEM.
Ijms 15 06062f2
Ijms 15 06062f3 1024
Figure 3. l-Ornithine levels correlate directly with l-arginine (A) and ADMA (B); but not in vitro arginase activity (C), in sputum samples obtained from the COPD patients. Spearman’s correlation coefficient and p-values are as indicated.
Figure 3. l-Ornithine levels correlate directly with l-arginine (A) and ADMA (B); but not in vitro arginase activity (C), in sputum samples obtained from the COPD patients. Spearman’s correlation coefficient and p-values are as indicated.
Ijms 15 06062f3
Ijms 15 06062f4 1024
Figure 4. Correlation of the fraction of exhaled nitric oxide (FeNO) with forced expiratory volume in one second (FEV1) (A) before (pre); and (B) after (post), inhaled bronchodilator (BD). Spearman’s correlation coefficient and p-values are as indicated.
Figure 4. Correlation of the fraction of exhaled nitric oxide (FeNO) with forced expiratory volume in one second (FEV1) (A) before (pre); and (B) after (post), inhaled bronchodilator (BD). Spearman’s correlation coefficient and p-values are as indicated.
Ijms 15 06062f4
Ijms 15 06062f5 1024
Figure 5. Arginase activity in COPD sputum correlates inversely with sputum NOx (A) and nitrite (B) levels, and with both pre (C) and post-bronchodilator (D) FEV1% predicted. Spearman’s correlation coefficient and p-values are as indicated.
Figure 5. Arginase activity in COPD sputum correlates inversely with sputum NOx (A) and nitrite (B) levels, and with both pre (C) and post-bronchodilator (D) FEV1% predicted. Spearman’s correlation coefficient and p-values are as indicated.
Ijms 15 06062f5
Table
Table 1. Patient demographics.
Table 1. Patient demographics.
MeasureMean ± SEM
n
Age (years) (mean ± SEM)62.3 ± 2.6
Height (cm) (mean ± SEM)174.0 ± 1.8
Weight (kg) (mean ± SEM)76.4 ± 3.0
Gender (m/f)8/2
Current/Ex smoker4/6
Pack years37 ± 5
COPD Diagnosis (years) (mean ± SEM)7 ± 2.6
Inhaled Glucocorticosteroids (y/n)6/4
Body Surface Area (m2) (mean ± SEM)1.90 ± 0.04
Table
Table 2. Sputum in vitro arginase activity, sputum nitrate + nitrate (NOx) levels and FeNO in COPD patients.
Table 2. Sputum in vitro arginase activity, sputum nitrate + nitrate (NOx) levels and FeNO in COPD patients.
MeasureMean ± SEM
Arginase activity (mU/mg protein)132.5 ± 28.4
FeNO (ppb)17 ± 4
Sputum NOx (μM)194 ± 70

Share and Cite

MDPI and ACS Style

Scott, J.A.; Duongh, M.; Young, A.W.; Subbarao, P.; Gauvreau, G.M.; Grasemann, H. Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). Int. J. Mol. Sci. 2014, 15, 6062-6071. https://doi.org/10.3390/ijms15046062

AMA Style

Scott JA, Duongh M, Young AW, Subbarao P, Gauvreau GM, Grasemann H. Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). International Journal of Molecular Sciences. 2014; 15(4):6062-6071. https://doi.org/10.3390/ijms15046062

Chicago/Turabian Style

Scott, Jeremy A., MyLinh Duongh, Aaron W. Young, Padmaja Subbarao, Gail M. Gauvreau, and Hartmut Grasemann. 2014. "Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD)" International Journal of Molecular Sciences 15, no. 4: 6062-6071. https://doi.org/10.3390/ijms15046062

APA Style

Scott, J. A., Duongh, M., Young, A. W., Subbarao, P., Gauvreau, G. M., & Grasemann, H. (2014). Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). International Journal of Molecular Sciences, 15(4), 6062-6071. https://doi.org/10.3390/ijms15046062

Article Metrics

Back to TopTop